Myriad Genetics, CancerCARE for Life announce agreement

Myriad Genetics (MYGN) and INTERLINK Care Management announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE’s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk with RiskScore Hereditary Cancer Test on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor.